Previous 10 | Next 10 |
LOS ANGELES , May 23, 2019 /PRNewswire/ -- Wedbush Securities is pleased to announce that Senior Vice President of Equity Research, Laura Chico , Ph.D., initiates coverage on six stocks in the Healthcare and BioTech space. Initiations are on the following: Acer Therapeutics Inc. (ACER...
Achillion Pharmaceuticals (NASDAQ: ACHN ) is up 7% premarket on light volume in response to preliminary data from a Phase 2 clinical trial evaluating factor D inhibitor ACH-4471 in patients with paroxysmal nocturnal hemoglobinuria (PNH), a rare inherited disorder characterized ...
Alexion Pharmaceuticals (Nasdaq: ALXN) today announced that management will present at the RBC Capital Markets Annual Healthcare Conference in New York, NY on Tuesday, May 21, 2019 at 9:30 a.m. ET. An audio webcast of the presentation will be available live. You can access the webcast at...
Alexion Pharmaceuticals (Nasdaq: ALXN) today announced that management will present at the UBS Global Healthcare Conference in New York, NY on Monday, May 20, 2019 at 11:30 a.m. ET. An audio webcast of the presentation will be available live. You can access the webcast at: http://ir.ale...
Catalyst Pharmaceuticals ( CPRX ) - As I'm writing this, the stock has lost 40% of its value in a single day after news came that the FDA approved Ruzurgi from Jacobus Pharma for LEMS (Lambert-Eaton myasthenic syndrome) patients age six to less than 17 years of age. This is the first app...
- New data published in NEJM confirm sustained three-year treatment effect - - Data will also be presented in Emerging Science session at American Academy of Neurology Annual Meeting - - SOLIRIS for NMOSD currently under regulatory review in the U.S., European Union and Japan; U.S...
News, Short Squeeze, Breakout and More Instantly...
Alexion Pharmaceuticals Inc. Company Name:
ALXN Stock Symbol:
NASDAQ Market:
Alexion Pharmaceuticals Inc. Website:
AstraZeneca (NASDAQ: AZN) hopes to soon close its planned acquisition of Alexion Pharmaceuticals (NASDAQ: ALXN) . The only hurdle left to jump is obtaining approval from United Kingdom regulators. In this Motley Fool Live video recorded on July 7 , Motley Fool contri...
This week, pharma and biotech giant AstraZeneca (NASDAQ: AZN) cleared its final hurdle in the proposed acquisition of orphan drug pharma company Alexion Pharmaceuticals (NASDAQ: ALXN) when it announced that the deal had received clearance from the United Kingdom's Compet...